Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …

Recent advances in acute myeloid leukemia biology and drug development have
transformed the therapeutic landscape for patients diagnosed with this disease. By …

Abstract With the Food and Drug Administration approval of 9 agents for different acute
myeloid leukemia (AML) indications, the prognosis and management of AML is evolving …

Management of AML involves choosing between purely palliative care, standard therapy
and investigational therapy (“clinical trial”). Even most older patients likely benefit from …

Overview: Evidence suggest that even patients aged 70 or above benefit from specific AML
therapy. The fundamental decision in AML then becomes whether to recommend standard …